Jubilant Life Sciences offers great risk reward: R Sreesankar

R Sreesankar, Head - Institutional Equities at Prabhudas Lilladher told CNBC-TV18, “We still believe that Jubilant Life Sciences offers a great risk reward. What we also think is in many of these cases where the midcaps have had a great rally, etc. probably at some point of time, we will see some of the weak holders probably exiting and booking profits to off-set for some of the losses that people would be seeing, etc. I am speaking about not institutions, even on the HNI side and various other sides. So, probably from a point of view, a correction, you have seen a correction which has happened in this company. We like the stock, our analyst likes the stock and we still have a target price of Rs 578.” “Va Tech Wabag have been through a very consolidation phase, as we call it. It is not a stock where you should see a large amount of volatility coming in. We also believe that it is a good long-term growth story. I do not think that there will be events which will make it move around in short-spikes that you will end up seeing. It will be a steady performer and we think this is going to be a good self cash generating story and we love such companies,” he said.